Such findings have also been observed in HER2-positive (amplification or overexpression) BTC tumours treated with monoclonal antibodies; in the MyPathway study, patients with gallbladder cancers tended to have better outcomes than other sub-histologies18. This evidence concerns the gene ERBB2 and neoplasm.